DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,993 filers reported holding DANAHER CORPORATION in Q3 2022. The put-call ratio across all filers is 1.00 and the average weighting 0.7%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $34,157,664 | +4.9% | 137,677 | +1.4% | 2.93% | +10.2% |
| Q2 2023 | $32,576,160 | -3.9% | 135,734 | +0.9% | 2.66% | -12.4% |
| Q1 2023 | $33,890,055 | -5.2% | 134,463 | -0.2% | 3.03% | -11.0% |
| Q4 2022 | $35,762,160 | -2.9% | 134,738 | -5.5% | 3.41% | -6.2% |
| Q3 2022 | $36,827,000 | -2.9% | 142,581 | -4.7% | 3.64% | +6.4% |
| Q2 2022 | $37,912,000 | -12.7% | 149,543 | +1.0% | 3.42% | +6.0% |
| Q1 2022 | $43,432,000 | -11.0% | 148,067 | -0.2% | 3.22% | -2.2% |
| Q4 2021 | $48,819,000 | +7.8% | 148,380 | -0.2% | 3.29% | +0.6% |
| Q3 2021 | $45,285,000 | +13.2% | 148,747 | -0.2% | 3.27% | +14.0% |
| Q2 2021 | $39,992,000 | +18.9% | 149,025 | -0.3% | 2.87% | +10.5% |
| Q1 2021 | $33,649,000 | -21.9% | 149,497 | -22.9% | 2.60% | -27.8% |
| Q4 2020 | $43,076,000 | -9.0% | 193,913 | -11.8% | 3.60% | -20.2% |
| Q3 2020 | $47,348,000 | -4.9% | 219,887 | -21.9% | 4.51% | -13.9% |
| Q2 2020 | $49,812,000 | +26.5% | 281,695 | -1.0% | 5.24% | +8.7% |
| Q1 2020 | $39,391,000 | -18.6% | 284,600 | -9.8% | 4.82% | -6.9% |
| Q4 2019 | $48,407,000 | +5.7% | 315,399 | -0.5% | 5.18% | -2.5% |
| Q3 2019 | $45,783,000 | +0.2% | 316,992 | -0.9% | 5.31% | -1.1% |
| Q2 2019 | $45,700,000 | +8.1% | 319,757 | -0.2% | 5.37% | -0.5% |
| Q1 2019 | $42,278,000 | +28.1% | 320,241 | +0.1% | 5.39% | +11.4% |
| Q4 2018 | $33,005,000 | -6.6% | 320,060 | -1.6% | 4.84% | +14.7% |
| Q3 2018 | $35,349,000 | +9.0% | 325,321 | -1.0% | 4.22% | +0.3% |
| Q2 2018 | $32,422,000 | +0.3% | 328,561 | -0.5% | 4.21% | +0.1% |
| Q1 2018 | $32,328,000 | +4.3% | 330,184 | -1.1% | 4.20% | +11.4% |
| Q4 2017 | $30,998,000 | +7.6% | 333,956 | -0.5% | 3.78% | +9.5% |
| Q3 2017 | $28,801,000 | +2.6% | 335,756 | +1.0% | 3.45% | -1.2% |
| Q2 2017 | $28,061,000 | -6.1% | 332,521 | -4.8% | 3.49% | -7.7% |
| Q1 2017 | $29,883,000 | +10.1% | 349,391 | +0.2% | 3.78% | +8.4% |
| Q4 2016 | $27,137,000 | -7.9% | 348,626 | -7.2% | 3.48% | -6.0% |
| Q3 2016 | $29,452,000 | -26.8% | 375,706 | -5.7% | 3.71% | -27.4% |
| Q2 2016 | $40,232,000 | +5.4% | 398,334 | -1.0% | 5.10% | +9.5% |
| Q1 2016 | $38,170,000 | +1.8% | 402,384 | -0.3% | 4.66% | +8.7% |
| Q4 2015 | $37,482,000 | +7.5% | 403,558 | -1.3% | 4.29% | +7.6% |
| Q3 2015 | $34,856,000 | +2.2% | 409,059 | +2.7% | 3.98% | +5.5% |
| Q2 2015 | $34,104,000 | +8.1% | 398,454 | +7.2% | 3.78% | -0.0% |
| Q1 2015 | $31,551,000 | -0.5% | 371,620 | +0.4% | 3.78% | +7.3% |
| Q4 2014 | $31,719,000 | +37.0% | 370,070 | +21.4% | 3.52% | +27.1% |
| Q3 2014 | $23,160,000 | – | 304,815 | – | 2.77% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |